ZIKV replication in human DCs was strongly limited when cells were treated with the hepatitis C virus RNA-derived RIG-I agonist (63), indicating that ZIKV is sensitive to the antiviral activity of IFN-I, although reduced secretion of inflammatory cytokines was observed during ZIKV infection (63). Here, RIGI is linked to Zika virus infectious disease.